Observatory on the impact of the
COVID-19 pandemic on the accessto treatments
2020-2021

Study performed by IQVIA with the non conditioning support ofFarmindustria© 2021. All rights reserved. IQVIA® is a registered trademark of IQVIA Inc. in the United States, the European Union, and various other countries.

Premise and objectives of the study
The pandemic had important effects on the initiation of treatments and access to treatments, with significant
consequences on the clinical outcomes
The sanitary emergency that hit the country is having a significative impact on the healthcare system. The complexity of thepandemic and the issues related to the management of infected people challenged the healthcare system with thesaturation of hospitals and intensive care, the need of defining procedures and paths dedicated to Covid-19 patients and thehome management of patients. Moreover, the pandemic produced a minor access to treatments for other diseases likeoncological, cardiological and respiratory ones. In fact, along with the concerns related to the management of infectedpatients, the extended lockdown had important effects also on the access to visits and treatments of non-Covid patients
producing significant consequences for patients’ health and healthcare system organization (hospital-territory integration,
remote patient management).

In this context IQVIA with the non conditioning contribution of Farmindustria realized a study, to be updated every threemonths, through an ad-hoc observatory to monitor the impact of the pandemic on the access to diagnosis and treatments
and its evolution in the following months. The study is based on the analysis of Real World Data gathered from a sample of
900 general practitioners and a panel of 450 onco-hematologists representative of the reference universes.

In this document the data related to the january-october 2020 period in comparison with the same period in 2019 arepresented. The study will follow for the entire 2021 with quarterly updates.

© IQVIA 2020. All rights reserved.

2

Main findings
The contraction of the entire
pharmaceutical sector (-3% MAT
09/2020) - for the first time inrecent years – unveils thelimitations of access totreatments both in the hospitaland in the pharmacy.
In the first ten months of 2020 it
has been detected a significant
decrease in the access todiagnosis and treatments in themain therapeutic areas comparedto the same period of theprevious year.
DATA SOURCEIQVIA LPD (Longitudinal Patient
Database) Records collected from thepatient management software – Panel of 900
GPs•

In the main respiratory and cardio-metabolic pathologies it has been identified a significant
contraction of the new diagnosis (-521.000 equal to a reduction of 12%), new treatments initiations(-277.000, -10%), specialistic visits (-1,5 million, - 30%) and requests of exams (-2.415.000, - 22%).

•In the respiratory area (COPD/asthma) it is observed a significant drop in new diagnosis (COPD:-62.000; Asthma: -158.000), new treatments (-46.000, -124.000), referral to specialists (-123.000,-129.000) and spirometry requests (-108.000, -127.000). The underlined drop during the first lockdown
is present also in the following period. In the cardiovascular area (atrial fibrillation/hearth failure) it isdetected a significant contraction in new diagnosis (atrial fibrillation -18.000, hearth failure -44.000), newtreatments (-4.000, -29.000), referrals to cardiologist (-81.000, -248.000) and requests of ECG (-64.000,-180.000). The slight improvement after the lockdown did not balance the losses.

•

Also, in the oncological area there is a significant contraction of access to diagnosis and treatments. In
the first lockdown period 18.000 postponed diagnosis are estimated. The partial recovery in the summer
months did not balance the drop: overall in october there are 30.000 cancer diagnosis less than theones made in the same period of the previous year. In particular, in the first 10 months there is areduction of the screening requests for breast (-7%), lung (-10%) and colon (-10%) cancer. In addition, it
is noted a contraction of new diagnosis for cancer (-11%), treatments initiations (-14%), surgeries (-17%)and hospitalization (-14%). After the initial interruption of screening and follow up visits, due to theclosure of many departments and ambulatories, it has been observed a partial recovery during summer
months, but it did not offset the contraction of diagnosis and treatments. Subsequently - in parallel to thesecond pandemic wave – it has been detected a new reduction in the accesses.

Oncology Dynamics: collection of patients
data forms - Panel of 450 oncohematologists© IQVIA 2020. All rights reserved.

3

The contraction of the pharmaceutical sector (-3%) shows the limitation ofaccess to treatments both in hospital and pharmacy
Evolution of the pharmaceutical during MAT 9/2020

Total(Sell-in Billion €)

23,1

12,7

10,4

22,4

12,3

Variation of thepharmaceutical by channel

Values(Sell-in Billion €)Total- 3,0%

Hospital and directpurchases- 2,9%

Pharmacy- 3,1%

10,1
Hospital and direct purchases
Pharmacy

MAT 9/2019

MAT 9/2020

Values are expressed considering the weighted average price for the hospital channel and direct purchases (included the DPC channel), ex-factory for pharmacy channel - Class A, A with note, Class C and Class H are taken into accountSource: IQVIA National Integrated Database September 2020
© IQVIA 2020. All rights reserved.

4

The first Covid-19 wave significantly affected the number of new diagnosis
and treatments, in addition to the requests of specialistic visits and exams
Dato Real World Data from GP – FOCUS: COPD, ASTHMA, ATRIAL FIBRILLATION, HEARTH FAILURE, HYPERTENSION, DIABETES-521.000-277.000 -1.498.000 -2.415.000[-12%][-10%][-30%][-22%]NEW
DIAGNOSISNEW
TREATMENTS

REFERRALS TO
SPECIALISTSTESTS/EXAMS∆ january-october 2020 vs 2019 YoY© IQVIA 2020. All rights reserved.

5

PRIMARY CARE AREA

In the first 10 months of the year, there was an important contraction of new
diagnosis, treatments and referrals to specialists among chronic pathologies
Analysis of activities january-october 19/20 (YoY – % values.)-45% -40% -35% -30% -25% -20% -15% -10%

-5%

-20%
-17%
-8%
-13%
-10%
-9%

New diagnosis-521.000

New treatments-277.000

-20%
-15%
-8%

-14%

Total deviation

Notes

0%

(-12%)(-10%)-3%• In all the therapeutic areas analyzed it is registered a reduction in new
diagnosis between 8-20% with respect to the same period in 2019 (-12% on
average)• COPD and Asthma are the most affected pathologies with -20% e -17% ofperformed diagnosis, followed by Atrial Fibrillation (-13%), hearth failure (-10%),hypertension (-9%) and diabetes (-8%)• New treatments are reduced on average by -10% Oct YTD with respect to 2019
• COPD and Asthma remain the most impacted (-20% e -15%), followed by FA (14%); diabetes (-8%), while hypertension (-6%) and hearth failure (-3%) are theless affected

-6%
-36%

Referral to specialist-1.498.000

Exams requests-2.415.000

-42%

-23%
-32%
-30%
-32%
-42%
-41%
-15%
-28%
-27%
-30%

COPD

AsthmaDiabetes

Atrial fibrillation

Hearth failure

Hypertension

Data source: IQVIA Longitudinal Patient Database (january 2019- october 2020)© IQVIA 2020. All rights reserved.

(-30%)(-22%)• The referrals to specialists have experienced a strong drop in all the therapeuticareas: -30% on average• The respiratory pathologies are the most hit with a collapse greater than 35%;
then the cardiological ones with a una reduction greater than 30%; thediabetes area is the least affected (-23%)• The requests of specialistic exams suffered an average impact of -22% in
relation to the previous year (spirometry, glycemia and ECG)
• Also in this case, the respiratory pathologies are the most affected (-41%), thenthe cardiological ones (around -28%); diabetes is the least impacted (-15%)

The impact of the deaths due to COVID-19, that affected the population object of the study in the period considered, on the estimation of the contraction of specialistic visits and exams requests
results minimal (the range is between -2,09% and -4,61%) according to the different therapeutic areas and it does not modify substantially the estimation made.
6

In the COPD area it is detected a significant drop of new diagnosis (-20%), newtreatments (-19%), referral to specialists (-35%) and spirometry requests (-42%). The
drop underlined after the first lockdown worsened during the year

COPD

COPD: comparison january-october 2020 vs 2019-20%
-62.000 patients

45
40
35
30
25

-30%

20

15

•

10

-47.700 pts.

5
0
Jan

Feb

Mar

Apr

May

Jun

Jul

2019

Aug

Sept

Oct

Nov

Dec

2020

Between february
and june 2020 the
new diagnosis of
COPD decreasedby 30% withrespect to thesame period in
2019

Thousands

NEW TREATMENTS•

Patients

Patients

Thousands

NEW DIAGNOSIS
50

50

40

Patients

40
30

-49%

20

0
Jan

Feb

Mar

Apr

May

10
0
Jan

Feb

Mar

Apr

May

Jun

2019

Jul

Aug

Sept

2020

Data source: IQVIA Longitudinal Patient Database (january 2019- october 2020)© IQVIA 2020. All rights reserved.

Oct

Nov

Dec

Jun

Jul

2019

Aug

Sept

Oct

Nov

Dec

2020

SPIROMETRY REQUESTS
Between february
and june 2020 thereferrals to
pulmonologist for
COPD decreasedby 49% withrespect to the same
period in 201960

Since the beginningof the year,
specialistic visit
requests for
COPD decreasedby ~123.000-42%-108.000 patients-75.200 pts.
50
40
30

-55%

20

•

Since thebeginning of theyear, there has
been a reduction of~46.000 COPD
new treatments

-27%

20

5

Thousands

50

•

•

25

10

Patients

Thousands-35%-123.000 patients-88.100 pts.

Between february
and june 2020 new
treatments
initiations for
COPD dropped by
27% with respect
to the same period
in 201930

15

Since thebeginning of theyear, there has
been a reductionof ~62.000 COPD
new diagnosis•

35

VISIT REQUESTS TO PULMONOLOGIST
60-19%-46.000 patients-35.700 pts.

45

10
0
Jan

Feb

Mar

Apr

May

Jun

2019

Jul

Aug
2020

Sept

Oct

Nov

Dec

• Between february
and june 2020
spirometry
requests for
COPD dropped by
55% with respect tothe same period in
2019• Since the beginningof the year, there
has been a drop of~108.000
spirometries for
COPD
7

ASTHMA

Also, in the asthma area it is observed a significative contraction of new diagnosis(-17%), new treatments (-16%), referrals to specialist (-40%) and spirometry requests (-41%).
The drop underlined after the first lockdown became even worse during the year
Asthma: comparison january-october 2020 vs 2019-17%
-158.000 patients

120

100

-20%

80
60
40
20

-106.400 pts.

0
Jan

Feb

Mar

Apr

May

Jun

2019

Jul

Aug

Sept

Oct

Nov

Dec

• Between february
and june 2020 the
new diagnosis ofasthma decreased
by 20% withrespect to the same
period in 2019
• Since the beginningof the year, there
has been a drop of~158.000 asthma
new diagnosis

Thousands

NEW TREATMENTS

Patients

Patients

Thousands

NEW DIAGNOSIS
140

140

-16%
-124.000 patients

120

100
80

-16%

60
40
20

-73.000 pts.

0
Jan

Feb

Mar

Apr

2020

35
30

-54%

20
15

Thousands

40

Jul

Aug

Sept

Oct

Nov

Dec

• Since the beginningof the year, there has
been a reduction of~124.000 new
asthma treatments

2020

SPIROMETRY REQUESTS

Patients

Thousands
Patients• Between february
and june 2020 thereferrals to
pulmonologist forasthma decreasedby 54% withrespect to the same
period in 2019-92.600 pts.

25

Jun

2019

VISIT REQUESTS TO PULMONOLOGIST45

May• Between february
and june 2020 new
treatments initiations
for Asthma dropped
by 16% with respect
to the same period in
2019

45

• Between february
and june 2020
spirometry
requests forasthma dropped
by 55% withrespect to the same
period in 2019-92.600 pts.

40
35
30
25

-55%

20
15

10

-40%
-129.000 patients

5
0

Jan

Feb

Mar

Apr

May

Jun

2019

Jul

Aug

Sept

2020

Data source: IQVIA Longitudinal Patient Database (january 2019- october 2020)© IQVIA 2020. All rights reserved.

Oct

Nov

Dec

• Since the beginningof the year,
specialistic visit
requests forasthma reduced by~129.00010-41%-127.000 patients

5
0

Jan

Feb

Mar

Apr

May

Jun

2019

Jul

Aug

2020

Sept

Oct

Nov

Dec

• Since the beginningof the year, there
has been a drop of~127.000
spirometries forasthma8

ATRIAL FIBRILLATION

In atrial fibrillation area there has been a significative contraction of new diagnosis (-13%), newtreatments (-11%), referrals to specialist (-31%) and ECG requests (-28%) starting from the
beginning of the year. The slight recovery after the lockdown did not balance the losses
Atrial fibrillation: comparison january-october 2020 vs 2019-13%
-44.000 patients

50
45
40
35

30

-26%

25
20
15
10

-45.000 pts.

5
0
Jan

Feb

Mar

Apr

May

Jun

2019

Jul

Aug

Sept

Oct

Nov

Dec

2020

• Between february
and june 2020 new
diagnosis of AF
decreased by 26%
with respect to thesame period of2019

Thousands

NEW TREATMENTS

Patients

Patients

Thousands

NEW DIAGNOSIS• Since the beginningof the year, there
has been a drop of~44.000 new
diagnosis for
atrial fibrillation-11%-29.000 patients

50
45
40
35

30
25

-22%

20
15
10

-28.500 pts.

5
0
Jan

Feb

Mar

Apr

May

Jun

2019

-31%
-248.000 patients

100
80

-43%

60

• Between february
and june 2020referrals to
cardiologist for AF
reduced by 43%
with respect to thesame period in
2019

40

Thousands

120-176.200 pts.
0
Jan

Feb

Mar

Apr

May

Jun

2019

Jul

Aug

Sept

2020

Data source: IQVIA Longitudinal Patient Database (january 2019- october 2020)© IQVIA 2020. All rights reserved.

Oct

Nov

Dec

Sept

Oct

Nov

Dec

-28%
-180.000 patients

120
100
80
60

-39%

40

20

Aug

2020

• Since the beginningof the year, there
has been a reductionof ~29.000 new
treatments for
atrial fibrillation

ECG REQUESTS

Patients

Patients

Thousands

VISIT REQUESTS TO CARDIOLOGISTJul• Between february
and june 2020 new
treatments
initiations for AF
dropped by 22% withrespect to the same
period in 2019

• Since the beginningof the year,
specialistic visit
requests for atrial
fibrillation reducedby ~248.000

20-127.200 pts.
0

Jan

Feb

Mar

Apr

May

Jun

2019

Jul

Aug

Sept

Oct

Nov

Dec

• Between february
and june 2020 ECG
requests for AF
decreased by 39%
with respect to thesame period in
2019• Since the beginningof the year, there
has been a drop of~180.000 ECG for
atrial fibrillation

2020
9

HEALTH FAILURE

Also, the health failure witnessed a drop during the lockdown, followed by a partial recovery
that does not offset the losses: there is a reduction of new diagnosis (-10%), new treatments(-4%), referrals to specialist(-30%) and ECG requests (-27%)
Health failure: comparison january-october 2020 vs 2019-10%
- 18.000 patients

30

25
20

-20%

15
10
5

-18.700 pts.

0
Jan

Feb

Mar

Apr

May

Jun

2019

Jul

Aug

Sept

Oct

Nov

Dec

2020

Thousands

NEW TREATMENTS• Between february
and june 2020 new
diagnosis ofhearth failure
decreased by 20%
with respect to thesame period in
2019

Patients

Patients

Thousands

NEW DIAGNOSIS
35

35

-4%
- 4.000 patients

30

25
20
15

-9%

10

• Since the beginningof the year, newdiagnosis ofhearth failure
reduced by~18.000

5-5.400 pts.

0
Jan

Feb

Mar

Apr

May

Jun

2019

-30%
- 81.000 patients

35
30
25

-41%

20
15
10
5

-57.000 pts.

0

Jan

Feb

Mar

Apr

May

Jun

2019

Jul

Aug

Sept

2020

Data source: IQVIA Longitudinal Patient Database (january 2019- october 2020)© IQVIA 2020. All rights reserved.

Oct

Nov

Dec

• Between february
and june 2020referrals to
cardiologist forhearth failure
decreased by 41%
with respect to thesame period in 2019
• Since the beginningof the year,
specialistic visit
requests forhearth failure
dropped by ~81.000

Thousands

40

Aug

Sept

Oct

Nov

Dec

2020

• Since the beginningof the year, there
has been a
reduction of ~4.000
new treatments
for hearth failure

ECG REQUESTS

Patients

Patients

Thousands

VISIT REQUESTS TO CARDIOLOGISTJul• Between february
and june 2020 new
treatments
initiations for hearth
failure dropped by
9% with respect tothe same period in
2019

40

-27%
- 64.000 patients

35
30
25

-37%

20
15
10
5

-46.300 pts.

0

Jan

Feb

Mar

Apr

May

Jun

2019

Jul

Aug

Sept

Oct

Nov

Dec

• Between february
and june 2020 ECG
requests for hearth
failure decreased
by 37% withrespect to the same
period in 2019
• Since the beginningof the year, there
has been a drop of~64.000 ECG forhearth failure

2020
10

HYPERTENSION

Hypertension had a significant fall during the lockdown, followed by a subsequent partial
recovery: in october it is observed a contraction in new diagnosis (-9%), new treatments(-4%), referrals to specialist (-32%) and ECG requests (-30%)
Hypertension: comparison january-october 2020 vs 2019-9%
- 186.000 patients

250
200

-22%

150

Thousands

NEW TREATMENTS• Between february
and june 2020 new
diagnosis of
hypertension
decreased by 22%
with respect to thesame period in
2019

Patients

Patients

Thousands

NEW DIAGNOSIS
300

100

300

-4%
- 55.000 patients

250
200
150

-13%

100

50

-231.200 pts.

0
Jan

Feb

Mar

Apr

May

Jun

2019

Jul

Aug

Sept

Oct

Nov

Dec

2020

• Since the beginningof the year, newdiagnosis of
hypertension
reduced by~186.00050-106.600 pts.

0
Jan

Feb

Mar

Apr

May

Jun

2019

-32%
- 944.000 patients

450
400
350
300
250

-45%

200

• Between february
and june 2020referrals to
cardiologist for
hypertension
decreased by 45%
with respect to thesame period in 2019

Thousands

500

Jul

Aug

Sept

Oct

Nov

Dec

2020

600

-30%
- 1.064.000 patients

500
400

-43%

300
200

150
100
50

-688.600 pts.

0

Jan

Feb

Mar

Apr

May

Jun

2019

Jul

Aug

Sept

2020

Data source: IQVIA Longitudinal Patient Database (january 2019- october 2020)© IQVIA 2020. All rights reserved.

Oct

Nov

Dec

• Since the beginningof the year, there
has been a
reduction of ~55.000
new treatments for
hypertension

ECG REQUESTS

Patients

Thousands

VISIT REQUESTS TO CARDIOLOGISTPatients• Between february
and june 2020 new
treatments
initiations for
hypertension
dropped by 13%
with respect to thesame period in 2019

• Since the beginningof the year,
specialistic visit
requests for
hypertension
dropped by ~944.000

100-765.700 pts.
0

Jan

Feb

Mar

Apr

May

Jun

2019

Jul

Aug

2020

Sept

Oct

Nov

Dec

• Between february
and june 2020 ECG
requests for
hypertension
dropped by 43%
with respect to thesame period in
2019• Since the beginningof the year, there
has been a drop of~1,1 million ECG
for hypertension
11

DIABETES

Diabetes had an important drop during the lockdown, which has not been recovered yet :since the beginning of 2020 there is a contraction in new diagnosis (-8%), new treatments(-5%), referrals to specialist (-20%) and glycemia tests (-15%)
Diabetes: comparison january-october 2020 vs 2019-8%
- 53.000 patients

90
80
70
60

-25%

50
40
30
20

-86.500 pts.

10
0
Jan

Feb

Mar

Apr

May

Jun

2019

Jul

Aug Sept

Oct

Nov

Dec

2020

• Between february
and june 2020 new
diagnosis of
diabetes decreased
by 25% withrespect to thesame period in
2019

Thousands

NEW TREATMENTS

Patients

Patients

Thousands

NEW DIAGNOSIS
100

100

-5%
- 20.000 patients

90
80
70
60
50
40

-17%

30

• Since the beginningof the year, newdiagnosis fordiabetes dropped
by ~53.000

20-40.400 pts.

10
0
Jan

Feb

Mar

150

-35%

100

-280.800 pts.
0

Feb

Mar

Apr

Jul

Aug Sept

Oct

Nov

Dec

2020

-15%
- 872.000 patients

900
800
700
600
500

-26%

400
300

50

Jan

• Between february
and june 2020referrals todiabetologists fordiabetes decreased
by 35% withrespect to the same
period in 2019

Thousands

200

Jun

May
2019

Jun

Jul

Aug Sept

2020

Data source: IQVIA Longitudinal Patient Database (january 2019- october 2020)© IQVIA 2020. All rights reserved.

Oct

Nov

Dec

• Since the beginningof the year, there
has been a
reduction of ~20.000
new treatments fordiabetes

GLYCEMIA TESTS REQUESTS

Patients

Thousands
Patients-20%- 313.000 patients

May
2019

VISIT REQUESTS TO DIABETOLOGIST
250

Apr

• Between february
and june 2020 new
treatments
initiations fordiabetes dropped by
17% with respect tothe same period in
2019• Since the beginningof the year,
specialistic visit
requests fordiabetes dropped
by ~313.000

200
100

-757.000 pts.

0

Jan

Feb

Mar

Apr

May
2019

Jun

Jul

Aug Sept

2020

Oct

Nov

Dec

• Between february
and june 2020
glycemia tests
requests fordiabetes droppedby 26% withrespect to the same
period in 2019
• Since the beginningof the year, there
has been a drop of~872.000 glycemia
tests for diabetes
12ONCOOGICAL SCREENING

From early 2020 in the oncological area the screening requests for breast, lung and colon
decreased by 7-10%, despite the partial recovery in summer months of the screening
Oncological screening: comparison january-october 2020 vs 2019
80%

-7%

80%

-10%

60%

60%

40%

40%

40%

20%

0%
Jan

Feb

Mar

Apr

May

Jun

Jul

Aug

Sept

Oct

-20%

20%

0%
Jan

Feb

Mar

Apr

May

Jun

Jul

Aug

Sept

Oct

-20%

Variation 2020 vs 2019 (MoM)

60%

Variation 2020 vs 2019 (MoM)

Variation 2020 vs 2019 (MoM)

80%

COLONOSCOPY REQUESTSPULMONARY CT SCAN REQUESTS FOR CANCER

BREAST CANCER SCREENING REQUESTS

20%

0%
Jan

-40%

-40%

-60%

-60%

-60%

-38%

• Between february and may 2020, the requests of
mammography screening to identify breast cancer
decreased by 38% with respect to the same period in 2019
• The greatest reduction is recorded between march andapril 2020, (-64%)• Between june and september it is observed an increaseof 27% vs 2019, that is quite substantial in june (+52%)• In october there is another drop of 14% vs 2019
Data source: IQVIA Longitudinal Patient Database (january 2019- october 2020)© IQVIA 2020. All rights reserved.

-80%

-18%

• Between february and may 2020, the requests of CT
scan to identify lung cancer decreased by 18% withrespect to the same period in 2019
• The greatest reduction is recorded between march andapril 2020, (-43%)• Between june and september it is observed an increaseof 9% vs 2019, that is quite substantial in june (+53%)• In october there is another drop of 25% vs 2019

Feb

Mar

Apr

May

Jun

Jul

Aug

Sept

Oct

-20%

-40%

-80%

-10%

-80%

-47%

• Between february and may 2020, the requests ofcolonoscopy to identify colon cancer decreased by
47% with respect to the same period in 2019
• The greatest reduction is recorded between march andapril 2020, (-65%)• Starting from june, there is an increase of 26% vs 2019;
the increase is more substantial in june (+51%), that was
followed by ups and down
13

ONCOLOGY

New diagnosis for cancer, treatment initiations, surgeries and hospitalizations dropped by 11-17%
with respect to the previous year. The partial recovery in summer months did not offset the losses.
They are estimated around 18.000 postponed diagnosis and 30.000 new diagnosis «lost»
Onco-hematology: diagnosis, treatments, hospitalizations, surgeries: comparison january-october 2020 vs 2019
NEW DIAGNOSIS-11%- 30.000 patients

10%

Variation 2020 vs 2019 (MoM)

TREATMENT INITIATION

5%
0%
-5%

Jan

Feb

Mar

Apr

May

Jun

Jul

Aug

Sept

Oct

-10%
-15%
-20%

Around 18.000
postponed diagnosis

-25%
-30%

-15%

-35%

• Between feb-june2020 new diagnosis
for onco-hematology
decreased by 15% vs.
2019. There are
estimated 18.000
postponed diagnosis• In October there are
estimated around30.000 diagnosed
patients less than theones for the same
period in previous
year (-11% vs PY)

15%

-14%
- 19.000 patients

10%

Variation 2020 vs 2019 (MoM)

15%

5%
0%
-5%

Jan

Feb

0%
Feb

Mar

Apr

-10%

Jun

Jul

Aug

-30%
-40%
-50%

Aug

Sept

Oct

• In october, nontreated patientswith an oncologicaldisease are around19.000 (-14% vs
PY)

-25%

-18%

Sept

Oct

30%

• Between february
and june surgeries
decreased by 20%
with respect to thesame period in 2019
• In october, patientswith cancer who did
not receive asurgery in «early»
stage are around8.000 (-17% vs PY)

-20%

-60%

May

Jul

-20%

-30%

-20%

Data source: IQVIA Oncology Dynamics Database (january 2019- september 2020) – data expanded to the universe© IQVIA 2020. All rights reserved.

-14%- 4.000 patients

20%

Variation 2020 vs 2019 (MoM)

Variation 2020 vs 2019 (MoM)

10%

Jun

HOSPITALIZATIONS FOR TREATMENTS-17%- 8.000 patients

20%

May

-15%

-35%

30%

Apr

-10%

SURGERIES

Jan

Mar

• Between february
and june 2020 theinitiations of new
oncohematologicaltreatments
dropped by 18%
with respect to thesame period in 2019

10%
0%
Jan

Feb

Mar

Apr

-10%
-20%
-30%
-40%
-50%
-60%

-16%

May

Jun

Jul

Aug

Sept

Oct

• Between february andjune 2020
hospitalizations
requests for oncohematologicaltreatments dropped by
16% with respect to thesame period in 2019
• In october, oncohematologicalpatients who are not
managed in
hospitalization arearound 4.000 (-14% vs
PY)14

In order to monitor the impact of Covid it is foreseen a quarterly monitoring ofreal world data for 2021, integrated by a semestral survey and with further
analysis and ad-hoc insights
2020
QTR 4

2021
QTR 1

QTR 2

QTR 3

QTR 4

Pilot study

1 wave• Real World Data (LPD and Onco
Dyn)
• Primary Market Research

2 wave• Real World Data (LPD and Onco
Dyn)

3 wave• Real World Data (LPD and Onco
Dyn)

4 wave• Real World Data (LPD and Onco
Dyn)
• Primary Market Research
15

Contacts
Isabella Cecchini
Principal, PMR
isabella.cecchini@iqvia.com+39 334 60 80 897

Francesca Rampi
Principal, Real World Data
francesca.rampi@iqvia.com+39 348 0029874

Elena De SantoEngagement Manager, Oncology
elena.desanto@iqvia.com+39 348 881 9160

Marco Zamboni
Sr Consultant, Real World Data
marco,zamboni@iqvia.com+39 349 4030392© 2021. All rights reserved. IQVIA® is a registered trademark of IQVIA Inc. in the United States, theEuropean Union, and various other countries.